Hemostatic gauze is a blood-contacting medical device that must undergo rigorous biocompatibility evaluation before market entry, with sensitization testing being one of the most critical endpoints. This article provides a comprehensive technical overview of sensitization evaluation for hemostatic gauze products based on ISO 10993-10, ISO 10993-12, GB/T 16886.10, and related international standards. It covers sample types, testing items, guinea pig and murine test methods, extraction conditions, regulatory applications, and frequently asked questions to support manufacturers, regulatory affairs professionals, and quality engineers.
Technical Overview
Sensitization evaluation assesses the potential of a medical device or its extractable chemical constituents to induce a Type IV delayed hypersensitivity reaction following repeated or prolonged contact with body tissue. Because hemostatic gauze is applied directly to bleeding wounds and therefore contacts blood and damaged tissue surfaces, regulatory authorities worldwide classify it as an external communicating device with blood or tissue contact, typically with limited contact duration of up to 24 hours. Under the risk-based framework of ISO 10993-1 (Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process), skin sensitization is a mandatory endpoint for this device category, regardless of whether the gauze is absorbable or non-absorbable.
Hemostatic gauze products may incorporate chemically active components, residual processing chemicals, sterilant residues such as ethylene oxide, crosslinking agents, surfactants, or finishing agents applied to textile substrates. Any of these substances can act as haptens that bind to skin proteins and trigger T-cell mediated immune responses in susceptible patients. A scientifically justified sensitization study, typically performed by accredited third-party laboratories in compliance with ISO/IEC 17025 quality management requirements, provides documented evidence of safety for regulatory submissions under frameworks such as the EU Medical Device Regulation (MDR), the United States FDA premarket notification pathway, and NMPA registration in China, where the GB/T 16886 series serves as the harmonized national adoption of ISO 10993.
Testing Samples
Sensitization evaluation applies to the finished, sterilized hemostatic gauze product whenever possible, because sterilization, packaging, and post-processing can alter the extractable chemical profile. Representative sample categories submitted for testing include the following:
Absorbent Cotton Gauze
Plain woven or non-woven cotton gauze used for wound packing and compression. Although cotton itself is generally considered biologically inert, sensitization testing is still required to verify the absence of residual pesticides, bleaching agents, optical brighteners, sizing chemicals, and sterilant byproducts such as ethylene oxide and ethylene chlorohydrin.
Oxidized Regenerated Cellulose (ORC) Gauze
Plant-derived absorbable knitted fabric that promotes clotting through platelet activation and its acidic degradation environment. Testing must account for degradation products, residual oxidants, low molecular weight organic acids, and any incorporated agents such as embedded thrombin or polyethylene glycol.
Chitosan-Based Hemostatic Gauze
Gauze coated or impregnated with chitosan acetate or other N-deacetylated chitosan derivatives that adhere to wounds and seal bleeding surfaces. Evaluation focuses on residual acetic acid, residual monomers, protein impurities from shellfish-derived raw materials, and the degree of deacetylation, all of which may influence immunological reactivity.
Calcium Alginate and Mineral-Based Hemostatic Gauze
Alginate fibers that exchange calcium for sodium at the wound site, as well as gauze incorporating kaolin, zeolite, or smectite minerals. Testing verifies that ion-exchange byproducts, residual processing salts, and mineral fines do not provoke delayed hypersensitivity responses.
Sample Preparation and Extraction
Sample preparation follows ISO 10993-12 (Biological evaluation of medical devices — Part 12: Sample preparation and reference materials). For porous, absorbent hemostatic materials, a ratio of 0.2 g of test article per milliliter of extraction vehicle is typically applied. Dual extraction is performed using a polar vehicle (physiological saline or culture medium) and a non-polar vehicle (sesame seed oil or cottonseed oil) to capture both water-soluble and lipophilic extractables. Common extraction conditions include 37 degrees Celsius for 72 hours for direct-use extracts in animal testing, while accelerated conditions such as 50 degrees Celsius for 72 hours or 70 degrees Celsius for 24 hours may be justified for screening purposes. Negative controls such as extraction vehicle alone and positive controls such as a known sensitizer are included in every valid study design.
Testing Items
The core testing program for sensitization evaluation of hemostatic gauze typically includes the following items, which are frequently bundled with irritation and cytotoxicity to form a complete biocompatibility panel:
- Skin sensitization potential of polar and non-polar extracts of the finished, sterilized product
- Intracutaneous (intradermal) reactivity of extracts, as a supporting local tolerance endpoint
- Primary skin irritation of extracts or of the device in direct contact application, where clinically relevant
- In vitro cytotoxicity per ISO 10993-5 as a complementary screening endpoint
- Chemical characterization and extractables/leachables profiling per ISO 10993-17 and ISO 10993-18 to support toxicological risk assessment of identified sensitizer candidates
- Ethylene oxide residual testing per ISO 10993-7 for products sterilized by EtO
- Analysis of degradation products per ISO 10993-13, ISO 10993-14, or ISO 10993-15 for absorbable hemostatic materials
Testing Methods
ISO 10993-10 (Tests for skin sensitization) and its Chinese counterpart GB/T 16886.10 define the accepted in vivo test designs. The current edition of ISO 10993-10 designates the murine Local Lymph Node Assay as the preferred first-choice method, with guinea pig methods retained in annexes for specific situations such as suspected strong oral or systemic toxicity of test materials in mice.
Guinea Pig Maximization Test (GPMT)
The GPMT is the most sensitive in vivo sensitization assay and is well suited to hemostatic gauze extracts. In the induction phase, intradermal injections combining test extract with Freund's Complete Adjuvant are administered, followed approximately one week later by topical induction over the same site. After a rest period of approximately 14 days, a challenge patch containing the test extract is applied to a naive flank site. Reactions are graded at 24, 48, and 72 hours after patch removal using the Magnusson-Kligman scale, where a score of zero indicates no visible change, one indicates discrete or patchy erythema, two indicates moderate confluent erythema, and three indicates severe erythema with edema. A positive sensitization response is concluded when a defined proportion of test animals exhibit grade one or greater responses exceeding those of the negative control group.
Buehler Closed Patch Test
The Buehler method relies entirely on topical application and is appropriate for products whose clinical exposure is limited to skin surface contact. Induction patches are applied weekly for three weeks, followed by a rest period and a single topical challenge. Grading follows the same Magnusson-Kligman scale, and interpretation compares the incidence and intensity of responses in the test group against the vehicle control group.
Murine Local Lymph Node Assay (LLNA)
The LLNA measures lymphocyte proliferation in the draining auricular lymph nodes of mice after repeated topical application of test extract to the ear. Radioactive tritiated thymidine methods, BrdU-ELISA methods, and DA (dilution assay) variants aligned with OECD Test Guidelines 429, 442A, and 442B are accepted. A Stimulation Index of three or greater conventionally indicates a positive sensitization result. The LLNA offers refined animal welfare characteristics, dose-response information, and a shorter study duration, making it increasingly preferred for extract-based testing of textile hemostatic products.
Study Design and Interpretation
All studies must include valid negative and positive controls, verify extract stability and concentration, and be conducted under Good Laboratory Practice conditions where required by the target regulatory jurisdiction. Where a positive result is obtained, follow-up chemical characterization, dose-response investigations, reformulation, modified sterilization residuals control, or a documented toxicological risk assessment may be required to demonstrate clinical safety.
Applications
Sensitization evaluation reports from accredited third-party laboratories are used across the full product lifecycle of hemostatic gauze:
- Regulatory submissions, including 510(k) premarket notifications and premarket approvals in the United States, CE technical documentation under the EU MDR, and NMPA device registration dossiers in China
- Biological safety evaluations and Biological Evaluation Files maintained under ISO 10993-1 in support of ISO 13485 quality management systems
- Verification of biological safety following product changes such as new raw material suppliers, modified weaving or coating processes, changed sterilization methods, or new packaging configurations
- Research and development screening for novel hemostatic materials, including chitosan derivatives, modified celluloses, and mineral hemostatic agents
- Post-market surveillance support and response to adverse event investigations involving suspected allergic reactions
- Scientific documentation for export market access in jurisdictions adopting ISO 10993, GB/T 16886, ASTM F1983, or JIS-based biocompatibility frameworks
FAQ
Question: Which standard governs the sensitization evaluation of hemostatic gauze?
Answer: ISO 10993-10 (Tests for skin sensitization) is the primary international standard, supported by ISO 10993-12 for sample preparation and ISO 10993-1 for endpoint selection. In China, the GB/T 16886.10 national standard applies and is technically aligned with ISO 10993-10. For products sold into the United States, the FDA guidance on the use of ISO 10993-1 is applied.
Question: How should the extraction ratio be selected for porous gauze materials?
Answer: For porous and absorbent devices such as hemostatic gauze, ISO 10993-12 specifies a ratio of 0.2 g of test material per milliliter of extraction vehicle. Justification must be documented when deviating from the standard ratio, and both polar and non-polar extractions are generally required.
Question: When should the LLNA be preferred over the GPMT?
Answer: The current edition of ISO 10993-10 recommends the LLNA as the first-choice method because it provides quantitative dose-response data and uses fewer animals. The GPMT remains appropriate when there are concerns about systemic exposure of extract components, when maximum sensitivity via adjuvant enhancement is desired, or when regulatory precedents for similar devices are based on guinea pig data.
Question: How long does a sensitization study typically take?
Answer: Including extract preparation, acclimatization, induction, rest, challenge, and reporting, a GPMT or Buehler study generally requires approximately eight to ten weeks, while an LLNA can be completed in approximately four to six weeks. Overall timelines should also account for sample sterilization verification and analytical support testing.
Question: Is sensitization testing still required if all constituent materials have a long history of safe use?
Answer: A documented materials-based justification may reduce testing scope, but for blood-contacting hemostatic devices, regulators commonly expect at least one sensitization study on the finished sterilized product, because manufacturing residuals, sterilization byproducts, and process contamination cannot be fully excluded through literature review alone.